



ASX ANNOUNCEMENT

7 June 2017

Van Leeuwenhoek Institute Initiates Cynata Research Coverage

Melbourne, Australia; 7 June 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that Van Leeuwenhoek Institute has initiated equity analyst coverage with the release of a new report on Cynata. Van Leeuwenhoek Institute provides expert independent equity research of innovative biotech companies in Europe, North America, Australia and emerging markets for institutional investors and professional investors throughout the US and Europe.

The full Van Leeuwenhoek research report can be viewed on Cynata's website at www.cynata.com.

Ends

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Andrew Ramadge, Australia Media Contact, 0475 797 471, andrew.ramadge@mcpartners.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.